A

Albireo Pharma Inc
F:BDQM

Watchlist Manager
Albireo Pharma Inc
F:BDQM
Watchlist
Price: 41.41 EUR 0.46%
Market Cap: 857.2m EUR

Net Margin
Albireo Pharma Inc

-228.5%
Current
-752%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-228.5%
=
Net Income
-131.1m
/
Revenue
57.4m

Net Margin Across Competitors

No Stocks Found

Albireo Pharma Inc
Glance View

Market Cap
856.9m EUR
Industry
Biotechnology

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2007-05-11. The firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

BDQM Intrinsic Value
Not Available
A
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-228.5%
=
Net Income
-131.1m
/
Revenue
57.4m
What is the Net Margin of Albireo Pharma Inc?

Based on Albireo Pharma Inc's most recent financial statements, the company has Net Margin of -228.5%.

Back to Top